Cognitive Neurocomputational Task Reliability and Clinical Applications Consortium: Study 2 (CNTRACS 2)
Cognitive Neurocomputational Task Reliability and Clinical Applications Consortium
In Study 2, investigators will recruit individuals with schizophrenia (SZ) and or schizoaffective disorder (SZA) and healthy controls (HC) using optimized behavioral tasks to replicate the behavioral findings from Study 1 and to assess additional psychometric properties such as test re-test reliability and practice effects.
Investigators will obtain data on: A) clinical symptoms, with detailed assessment of hallucinations and delusions; B) community functioning; and C) functional capacity, allowing us to examine clinical validity. To generate a sample with sufficient variation in hallucinations and delusions, investigators will recruit the following groups that balance feasibility with clinical relevance: A) healthy controls [HC, N=125]; B) schizophrenia and schizoaffective disorder [SZ/SZA, N=200]). Investigators anticipate a ~20% screen fail/drop-out rate based upon prior studies. Thus, investigators will run an additional 40 SZ/SZA and 15 HC.
Investigators will administer tasks optimized in Aim 1 without electroencephalogram (EEG), to this new sample of individuals with SZ/SZA and HC.
All participants will be retested after approximately 28 days and repeat clinical assessments. Although the investigators' goal is to shorten task length using the Study 1 analyses, they will administer longer tasks than optimal for public dissemination in Study 2 to determine the minimum number of trials required for acceptable reliability. Study 2 will use the same clinical and functional measures as Study 1.
연구 개요
상태
상태
정황
정황
개입 / 치료
개입 / 치료
상세 설명
Each participant will complete 3 sessions (~3 hours each) within 3 weeks at baseline. The first session includes clinical, self-report, proxy function, and community function assessments. Sessions 2-3 are for task. Each participant will complete 7 tasks across these sessions. Task order will be counterbalanced across sessions. Participants will return after 28 days and repeat these same 3 sessions.
Clinical Assessment and Self-Report: A trained assessor will diagnose participants using the Structured Clinical Interview (SCID-5) for Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5) Text Revision 59 (TR59). Clinicians will rate hallucination and delusion symptom severity with the Chicago Hallucinations Assessment Tool (CHAT) and the Brief Psychiatric Rating Scale (BPRS). Investigators will use the Psychotic Symptom Rating Scales (PSYRATS) to evaluate the degree of preoccupation, conviction, distress, and life disruption associated with hallucinations and delusions elicited on the BPRS and CHAT. To address specificity, investigators will administer the Clinical Assessment Interview for Negative Symptoms (CAINS). For self-report, investigators will use the Beliefs about Voices Scale which assesses attributions about the origin and power of voices, and the Yale Control Over Perceptual Experiences (COPE) scale, which evaluates the extent to which people feel they can exert control over their voices. Investigators also will use the Peters Delusion Inventory to assess the extent of delusional thinking, supplemented by the Green Paranoia Scale to provide additional coverage of persecutory beliefs. To assess specificity, investigators will use the Patient Health Questionnaire (PHQ-9) to assess depression, the Generalized Anxiety Disorder Scale (GAD-7) to assess anxiety, and the Motivation and Pleasure Scale-Self-Report (MAP-SR) to assess anhedonia and motivation. Investigators will conduct a principal components analysis (PCA) on measures of the same construct (e.g., delusions) and perform primary analyses using the first principal component, followed by secondary analyses of specific measures False Discovery Rate (FDR) correction.
Community Function: Patients will complete the Specific Levels of Functioning (SLOF) scale, a validated scale of work and community function. National Institute of Mental Health (NIMH) Common Data Elements: Investigators will acquire the additional NIMH Tier 1 Common Data elements (e.g., World Health Organization Disability Assessment Schedule 2 (WHODAS 2.0) & DSM-5 Symptom Measure). Investigators will include standard general cognitive measures to assess the specificity of effects beyond general cognitive impairment. Specifically, investigators will include validated online measures from TestMyBrain (https://www.testmybrain.org/using-tmb/research.html; Digit Symbol Coding, Vocabulary, and Matrix Reasoning), as in our prior work in both clinical and healthy populations.
연구 유형
연구 유형
등록 (추정된)
등록
단계
단계
- 해당 없음
연락처 및 위치
연구 연락처
연구 연락처
- 이름: Deanna Barch, Ph.D.
- 전화번호: 314-935-8729
- 이메일: dbarch@wustl.edu
연구 연락처 백업
- 이름: Lori Ingram
- 전화번호: 314-747-2160
- 이메일: ingram@wustl.edu
연구 장소
-
-
California
-
Irvine, California, 미국, 92868
- University of California Irvine
-
연락하다:
- Cameron Carter, MD
- 전화번호: 916-734-2972
- 이메일: cscarte1@hs.uci.edu
-
-
Illinois
-
Chicago, Illinois, 미국, 60637
- The University of Chicago
-
연락하다:
- Molly Erickson, PhD
- 전화번호: (773) 702-5855
- 이메일: merickson1@yoda.bsd.uchicago.edu
-
연락하다:
- Nicole Ogbuagu
- 전화번호: 773-795-2633
- 이메일: nicoleogbuagu@uchicago.edu
-
-
Maryland
-
Baltimore, Maryland, 미국, 21201
- University of Maryland, Baltimore
-
연락하다:
- James Gold, MD
- 전화번호: (410) 402-7871
- 이메일: jgold@som.umaryland.edu
-
-
Minnesota
-
Minneapolis, Minnesota, 미국, 55455
- University of Minnesota
-
연락하다:
- Angus Macdonald III, PhD
- 전화번호: 612-624-3813
- 이메일: angus@umn.edu
-
연락하다:
- CNTRACS Study Team
- 전화번호: 651-558-1275
- 이메일: CNTRACS@umn.edu
-
-
Missouri
-
St Louis, Missouri, 미국, 63110
- Washington University
-
연락하다:
- Deanna Barch, Ph.D.
- 전화번호: 314-935-8729
- 이메일: dbarch@wustl.edu
-
연락하다:
- Lori Ingram
- 전화번호: 314-747-2160
- 이메일: ingram@wustl.edu
-
-
참여기준
자격 기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
General Inclusion
- age 18 to 59 ;
- no substance disorder in past six months (confirmed with urine drug screens and breathalyzers);
- no clinically significant head injury or neurological disease;
- WechslerTest of Adult Reading (WTAR) score =16+.
Group Specific Criteria: Schizophrenia/SchizoaffectiveDisorder (SZ/SZA):
- Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5) diagnosis ofschizophrenia or schizoaffective;
- no medication changes in prior month or anticipated in the next month or not taking medications;
- outpatient or partial hospital if unmedicated
- Healthy Controls (HC):
- no Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5) - Psychosis or BipolarDisorder;
- no family history of psychosis or bipolar
Exclusion Criteria:
Healthy Controls (HC):
- Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5)Psychosis or Bipolar Disorder diagnosis
- Family history of psychosis, bipolar, or Schizophrenia/Schizoaffective Disorder (SZ/SZA)
additional exclusion criteria for the unmedicated individuals are:
- not in acute exacerbation requiring immediate hospitalization or treatment;
- self-reported medication non-compliance for at least the four previous weeks
- never having started medications
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 기초 과학
- 할당: 해당 없음
- 중재 모델: 단일 그룹 할당
- 마스킹: 없음(오픈 라벨)
연구는 무엇을 측정합니까?
주요 결과 측정
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Sine Wave Speech Task Performance
기간: 1 hour
|
Percentage of trials coded as speech or not vs Dprime |
1 hour
|
|
Volatility Task Performance
기간: 1 hour
|
Percent correct bag captures during periods of stability vs. instability - patients worse in both, but particularly impaired in instability vs. Environmental volatility belief parameter |
1 hour
|
|
Minnesota Trust Game Performance
기간: 1 hour
|
Percent of trusting choices depending on decision-agent and temptation vs. spite-guilt beliefs estimate |
1 hour
|
|
Dynamic Trust Game Performance
기간: 1 hour
|
Trust indexed by mean investment versus learning rates |
1 hour
|
|
Motion Perception Task Performance
기간: 1 hour
|
With 15 degrees of initial or changed direction vs. the probability of failing to update |
1 hour
|
|
Kamin Blocking Task Performance
기간: 1 hour
|
Number of times participant predict allergy following blocked cue vs. prediction errors and learning rates |
1 hour
|
|
Choice Probabilistic Reversal Performance Task
기간: 1 hour
|
Win-switch rate (higher in patients, particularly paranoid patients) vs. (prior on volatility belief updating in response to volatility |
1 hour
|
공동 작업자 및 조사자
협력자
협력자
수사관
수사관
- 수석 연구원: Deanna Barch, PhD, Washington University School of Medicine
간행물 및 유용한 링크
일반 간행물
- Li C, Boudewyn MA, Barch DM, Carter CS, Frank MJ, Gold JM, MacDonald AW 3rd, Ragland JD, Silverstein SM, Yonelinas A, Luck SJ, Erickson MA. Impacted and preserved sub-domains of cognitive control in schizophrenia. Neuropsychologia. 2026 Sep 9;230:109503. doi: 10.1016/j.neuropsychologia.2026.109503. Epub 2026 May 25.
- Boudewyn MA, Erickson MA, Winsler K, Barch DM, Carter CS, Frank MJ, Gold JM, MacDonald AW 3rd, Ragland JD, Silverstein SM, Yonelinas AP, Luck SJ. Assessing Trial-by-Trial Electrophysiological and Behavioral Markers of Attentional Control and Sensory Precision in Psychotic and Mood Disorders. Schizophr Bull. 2025 Mar 14;51(2):543-555. doi: 10.1093/schbul/sbae038.
- MacDonald AW, Patzelt E, Kurth-Nelson Z, Barch DM, Carter CS, Gold JM, Ragland JD, Silverstein SM. Computational modeling of reversal learning impairments in schizophrenia and bipolar disorder reveals shared failure to exploit rewards. J Psychopathol Clin Sci. 2025 Apr;134(3):262-271. doi: 10.1037/abn0000944. Epub 2025 Mar 10.
- Erickson MA, Boudewyn MA, Winsler K, Li C, Barch DM, Carter CS, Frank MJ, Gold JM, MacDonald AW 3rd, Ragland JD, Silverstein SM, Yonelinas A, Luck SJ. Dysfunctional Alpha Modulation as a Mechanism of Working Memory Impairment in Serious Mental Illness. Biol Psychiatry Cogn Neurosci Neuroimaging. 2024 Dec;9(12):1271-1280. doi: 10.1016/j.bpsc.2024.07.022. Epub 2024 Aug 6.
- Barch DM, Boudewyn MA, Carter CC, Erickson M, Frank MJ, Gold JM, Luck SJ, MacDonald AW 3rd, Ragland JD, Ranganath C, Silverstein SM, Yonelinas A. Cognitive [Computational] Neuroscience Test Reliability and Clinical Applications for Serious Mental Illness (CNTRaCS) Consortium: Progress and Future Directions. Curr Top Behav Neurosci. 2023;63:19-60. doi: 10.1007/7854_2022_391.
- Rac-Lubashevsky R, Cremer A, Collins AGE, Frank MJ, Schwabe L. Neural Index of Reinforcement Learning Predicts Improved Stimulus-Response Retention under High Working Memory Load. J Neurosci. 2023 Apr 26;43(17):3131-3143. doi: 10.1523/JNEUROSCI.1274-22.2023. Epub 2023 Mar 17.
- Kwashie AN, Ma Y, Barch DM, Chafee M, Ragland JD, Silverstein SM, Carter CS, Gold JM, MacDonald AW 3rd. Comparing the functional neuroanatomy of proactive and reactive control between patients with schizophrenia and healthy controls. Cogn Affect Behav Neurosci. 2023 Feb;23(1):203-215. doi: 10.3758/s13415-022-01036-6. Epub 2022 Nov 23.
- Liu RG, Frank MJ. Hierarchical clustering optimizes the tradeoff between compositionality and expressivity of task structures for flexible reinforcement learning. Artif Intell. 2022 Nov;312:103770. doi: 10.1016/j.artint.2022.103770. Epub 2022 Aug 5.
- Pratt DN, Barch DM, Carter CS, Gold JM, Ragland JD, Silverstein SM, MacDonald AW. Reliability and Replicability of Implicit and Explicit Reinforcement Learning Paradigms in People With Psychotic Disorders. Schizophr Bull. 2021 Apr 29;47(3):731-739. doi: 10.1093/schbul/sbaa165.
- Geana A, Barch DM, Gold JM, Carter CS, MacDonald AW 3rd, Ragland JD, Silverstein SM, Frank MJ. Using Computational Modeling to Capture Schizophrenia-Specific Reinforcement Learning Differences and Their Implications on Patient Classification. Biol Psychiatry Cogn Neurosci Neuroimaging. 2022 Oct;7(10):1035-1046. doi: 10.1016/j.bpsc.2021.03.017. Epub 2021 Apr 18.
- Hamid AA, Frank MJ, Moore CI. Wave-like dopamine dynamics as a mechanism for spatiotemporal credit assignment. Cell. 2021 May 13;184(10):2733-2749.e16. doi: 10.1016/j.cell.2021.03.046. Epub 2021 Apr 15.
- Moran EK, Gold JM, Carter CS, MacDonald AW 3rd, Ragland JD, Silverstein SM, Luck SJ, Barch DM. Both unmedicated and medicated individuals with schizophrenia show impairments across a wide array of cognitive and reinforcement learning tasks. Psychol Med. 2022 Apr;52(6):1115-1125. doi: 10.1017/S003329172000286X. Epub 2020 Aug 17.
- Pedersen ML, Frank MJ. Simultaneous Hierarchical Bayesian Parameter Estimation for Reinforcement Learning and Drift Diffusion Models: a Tutorial and Links to Neural Data. Comput Brain Behav. 2020 Dec;3(4):458-471. doi: 10.1007/s42113-020-00084-w. Epub 2020 May 26.
- Ray KL, Ragland JD, MacDonald AW, Gold JM, Silverstein SM, Barch DM, Carter CS. Dynamic reorganization of the frontal parietal network during cognitive control and episodic memory. Cogn Affect Behav Neurosci. 2020 Feb;20(1):76-90. doi: 10.3758/s13415-019-00753-9.
- Smucny J, Iosif AM, Eaton NR, Lesh TA, Ragland JD, Barch DM, Gold JM, Strauss ME, MacDonald AW, Silverstein SM, Carter CS. Latent Profiles of Cognitive Control, Episodic Memory, and Visual Perception Across Psychiatric Disorders Reveal a Dimensional Structure. Schizophr Bull. 2020 Jan 4;46(1):154-162. doi: 10.1093/schbul/sbz025.
- Gold JM, Barch DM, Feuerstahler LM, Carter CS, MacDonald AW, Ragland JD, Silverstein SM, Strauss ME, Luck SJ. Working Memory Impairment Across Psychotic disorders. Schizophr Bull. 2019 Jun 18;45(4):804-812. doi: 10.1093/schbul/sby134.
- Smucny J, Barch DM, Gold JM, Strauss ME, MacDonald AW 3rd, Boudewyn MA, Ragland JD, Silverstein SM, Carter CS. Cross-diagnostic analysis of cognitive control in mental illness: Insights from the CNTRACS consortium. Schizophr Res. 2019 Jun;208:377-383. doi: 10.1016/j.schres.2019.01.018. Epub 2019 Jan 28.
- Ermel J, Carter CS, Gold JM, MacDonald AW 3rd, Daniel Ragland J, Silverstein SM, Strauss ME, Barch DM. Self versus informant reports on the specific levels of functioning scale: Relationships to depression and cognition in schizophrenia and schizoaffective disorder. Schizophr Res Cogn. 2017 May 9;9:1-7. doi: 10.1016/j.scog.2017.04.001. eCollection 2017 Sep.
- Barch DM, Carter CS, Gold JM, Johnson SL, Kring AM, MacDonald AW, Pizzagalli DA, Ragland JD, Silverstein SM, Strauss ME. Explicit and implicit reinforcement learning across the psychosis spectrum. J Abnorm Psychol. 2017 Jul;126(5):694-711. doi: 10.1037/abn0000259. Epub 2017 Apr 13.
- Lopez-Garcia P, Lesh TA, Salo T, Barch DM, MacDonald AW 3rd, Gold JM, Ragland JD, Strauss M, Silverstein SM, Carter CS. The neural circuitry supporting goal maintenance during cognitive control: a comparison of expectancy AX-CPT and dot probe expectancy paradigms. Cogn Affect Behav Neurosci. 2016 Feb;16(1):164-75. doi: 10.3758/s13415-015-0384-1.
- Ragland JD, Ranganath C, Harms MP, Barch DM, Gold JM, Layher E, Lesh TA, MacDonald AW 3rd, Niendam TA, Phillips J, Silverstein SM, Yonelinas AP, Carter CS. Functional and Neuroanatomic Specificity of Episodic Memory Dysfunction in Schizophrenia: A Functional Magnetic Resonance Imaging Study of the Relational and Item-Specific Encoding Task. JAMA Psychiatry. 2015 Sep;72(9):909-16. doi: 10.1001/jamapsychiatry.2015.0276.
- Silverstein SM, Harms MP, Carter CS, Gold JM, Keane BP, MacDonald A 3rd, Ragland JD, Barch DM. Cortical contributions to impaired contour integration in schizophrenia. Neuropsychologia. 2015 Aug;75:469-80. doi: 10.1016/j.neuropsychologia.2015.07.003. Epub 2015 Jul 6.
- Sheffield JM, Repovs G, Harms MP, Carter CS, Gold JM, MacDonald AW 3rd, Daniel Ragland J, Silverstein SM, Godwin D, Barch DM. Fronto-parietal and cingulo-opercular network integrity and cognition in health and schizophrenia. Neuropsychologia. 2015 Jul;73:82-93. doi: 10.1016/j.neuropsychologia.2015.05.006. Epub 2015 May 13.
- Barch DM, Sheffield JM. Cognitive impairments in psychotic disorders: common mechanisms and measurement. World Psychiatry. 2014 Oct;13(3):224-32. doi: 10.1002/wps.20145.
- Strauss ME, McLouth CJ, Barch DM, Carter CS, Gold JM, Luck SJ, MacDonald AW 3rd, Ragland JD, Ranganath C, Keane BP, Silverstein SM. Temporal stability and moderating effects of age and sex on CNTRaCS task performance. Schizophr Bull. 2014 Jul;40(4):835-44. doi: 10.1093/schbul/sbt089. Epub 2013 Jul 1.
- Owoso A, Carter CS, Gold JM, MacDonald AW 3rd, Ragland JD, Silverstein SM, Strauss ME, Barch DM. Cognition in schizophrenia and schizo-affective disorder: impairments that are more similar than different. Psychol Med. 2013 Dec;43(12):2535-45. doi: 10.1017/S0033291713000536. Epub 2013 Mar 25.
- Keane BP, Silverstein SM, Barch DM, Carter CS, Gold JM, Kovacs I, MacDonald AW 3rd, Ragland JD, Strauss ME. The spatial range of contour integration deficits in schizophrenia. Exp Brain Res. 2012 Aug;220(3-4):251-9. doi: 10.1007/s00221-012-3134-4. Epub 2012 Jun 19.
- Barch DM, Mathalon DH. Using brain imaging measures in studies of procognitive pharmacologic agents in schizophrenia: psychometric and quality assurance considerations. Biol Psychiatry. 2011 Jul 1;70(1):13-8. doi: 10.1016/j.biopsych.2011.01.004. Epub 2011 Feb 21.
- Boudewyn MA, Erickson MA, Winsler K, Ragland JD, Yonelinas A, Frank M, Silverstein SM, Gold J, MacDonald AW 3rd, Carter CS, Barch DM, Luck SJ. Managing EEG studies: How to prepare and what to do once data collection has begun. Psychophysiology. 2023 Nov;60(11):e14365. doi: 10.1111/psyp.14365. Epub 2023 Jun 14.
- Sheffield JM, Gold JM, Strauss ME, Carter CS, MacDonald AW 3rd, Ragland JD, Silverstein SM, Barch DM. Common and specific cognitive deficits in schizophrenia: relationships to function. Cogn Affect Behav Neurosci. 2014 Mar;14(1):161-74. doi: 10.3758/s13415-013-0211-5.
연구 기록 날짜
연구 주요 날짜
연구 시작 (추정된)
연구 시작
기본 완료 (추정된)
기본 완료
연구 완료 (추정된)
연구 완료
연구 등록 날짜
최초 제출
최초 제출
QC 기준을 충족하는 최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
처음 게시됨
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
마지막 업데이트 게시됨
QC 기준을 충족하는 마지막 업데이트 제출
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
기타 연구 ID 번호
- 201904012: Study 2
- 2R01MH084840 (미국 NIH 보조금/계약)
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
IPD 계획 설명
Our plan is to share de-identified participant data through the National Data Archive (NDA) as required by the National Institute of Mental Health (NIMH)
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .